Several third-generation EGFR TKIs, which irreversibly block T790M mutant EGFR, have shown to be effective in patients with acquired EGFR mutant lung cancer patients who acquired T790M after treatment failure with previous EGFR TKIs [11, 12]. The gene discussed is EGFR; the disease is lung cancer.